CJC-1295 No DAC Spray

What Is CJC-1295 No DAC?

CJC-1295 No DAC is a synthetic 29-residue peptide commonly identified by the sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg. Scientific and vendor literature describes it as an analogue of the first 29 amino acids of human growth hormone-releasing hormone, GHRH(1-29), carrying four substitutions — D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ — and it is commonly cross-referenced as Modified GRF (1-29).

This is a distinct molecule from CJC-1295 With DAC, which carries an additional chemical group that covalently binds circulating albumin. Foundational pharmacology publications using the "CJC-1295" name specifically studied the DAC-conjugated form; that data should not be assumed to describe this No DAC material without confirming which exact form was studied.

Research on CJC-1295 No DAC has examined its interaction with biological systems associated with the growth hormone axis, including studies of GHRH-receptor (GHRHR) binding on anterior pituitary somatotrophs. Published experimental work associated with the broader "CJC-1295" name has investigated cellular, animal, and — for the DAC-conjugated form specifically — human models. These findings provide research context but should not be interpreted as evidence of clinical efficacy or as a medical recommendation for this No DAC product.

CJC-1295 No DAC Spray for Laboratory Research

A spray format can be relevant when researchers are studying peptide formulation science, delivery-format comparison, or analytical reproducibility in controlled experimental models. "Spray" describes this product's physical presentation; it does not by itself establish an administration route, and no route-specific claim is made for this product.

For laboratory work, researchers should distinguish between the scientific literature surrounding the "CJC-1295" name generally and the specifications of this particular commercial research material — and, specifically, should confirm whether cited literature describes the No DAC or With DAC form before applying it to this product. Experimental results depend on factors such as peptide identity, purity, formulation, experimental model, analytical method, and study design.

Helix Bio positions its peptide catalog for research and laboratory purposes only. Product documentation and lot-specific analytical information should be reviewed before a material is incorporated into an experimental workflow.

Research Context

CJC-1295 No DAC and the broader "CJC-1295" name have been investigated in several areas of basic and translational research, including:

• GHRH-receptor (GHRHR) interactions
• Pituitary somatotroph and growth-hormone-axis signaling
• Comparative research distinguishing the No DAC and With DAC forms
• Peptide structure and biochemical characterization
• Structure-activity research relative to Sermorelin (GRF(1-29))
• Cellular and animal-model studies
• Peptide formulation and analytical-method research

The existence of published research does not establish that CJC-1295 No DAC Spray is safe or effective for use in humans. CJC-1295 is not an FDA-approved drug in the United States, and regulatory status should be distinguished from scientific interest or experimental literature.

• CJC-1295 No DAC research peptide in spray format
• Synthetic 29-residue GHRH(1-29) analogue research material
• Commonly cross-referenced as Modified GRF (1-29)
• Molecularly distinct from CJC-1295 With DAC
• Relevant to GHRH-receptor and pituitary-axis studies
• Suitable for controlled laboratory investigation
• Research-focused product positioning
• Lot-specific documentation should be reviewed before experimental use
• Intended exclusively for research and laboratory purposes
• Not intended for human or veterinary consumption

Researchers evaluating peptide materials generally need more than a product name. Identity, purity, analytical documentation, storage requirements, and traceability can all affect the interpretation of experimental results — and this matters more than usual for CJC-1295, given how inconsistently the "CJC-1295" name is applied across the market to two molecularly distinct products.

Helix Bio states that its research peptide catalog uses independent HPLC testing for purity assessment and mass spectrometry for molecular identity confirmation. The company also states that batch-specific Certificates of Analysis are available for its products.

For CJC-1295 No DAC Spray, researchers should verify the applicable product documentation and current lot information rather than relying solely on a general product description.

CJC-1295 No DAC Spray is intended for qualified users working in legitimate laboratory or scientific research environments, including:

• Academic research laboratories
• Biotechnology laboratories
• Pharmaceutical research groups
• Contract research organizations
• Qualified scientific researchers
• Educational research institutions
• Laboratories conducting endocrine-axis or peptide research

The product is not intended for personal experimentation, self-administration, human consumption, veterinary use, or medical treatment.

CJC-1295 No DAC has a documented research history connected to the broader "CJC-1295" and GHRH-analogue literature, particularly in endocrinology and peptide biology.

GHRH-Receptor and Pituitary Signaling Research

Researchers have investigated GHRH(1-29) analogues, including CJC-1295 No DAC, in relation to GHRH-receptor (GHRHR) binding on anterior pituitary somatotrophs and downstream pulsatile growth hormone release. Much of the specific pharmacodynamic data published under the "CJC-1295" name describes the DAC-conjugated form; No DAC-specific pharmacodynamic evidence is comparatively limited.

These studies can provide background for basic endocrine research but should not be extrapolated directly into human therapeutic outcomes.

Peptide Structure Research

CJC-1295 No DAC is a synthetic 29-residue peptide related structurally to Sermorelin (GRF(1-29)), differing by four substitutions. Its defined amino-acid sequence makes it relevant to structure-function studies examining how peptide composition and molecular modifications influence receptor interactions.

No DAC vs. With DAC Comparative Research

Because "CJC-1295" has been applied inconsistently across the market to two molecularly distinct products, comparative and analytical research relevant to this compound often focuses on confirming which exact form is present in a given study or product lot, and on distinguishing pharmacokinetic data reported for the DAC-conjugated form from data specific to No DAC.

Cell and Molecular Research

Published studies associated with the GHRH-analogue class have also examined receptor-binding and cellular signaling systems relevant to CJC-1295 No DAC. Researchers should evaluate each publication according to its model, methodology, exact compound form, and endpoints rather than assuming that findings from one experimental system, or from the DAC-conjugated form, apply universally.

Analytical quality is important when working with research peptides because impurities, degradation products, incorrect identity, or inconsistent concentration can introduce unwanted variables into an experiment. For CJC-1295 No DAC specifically, confirming which form — No DAC or With DAC — a lot actually contains is itself part of identity verification, since the two differ by roughly 279 Da in molecular weight.

Helix Bio states that its peptide materials are subjected to independent HPLC testing for purity and mass spectrometry for molecular identity. It also states that batch-specific Certificates of Analysis are available for its products.

For a specific CJC-1295 No DAC Spray lot, researchers should consult the applicable COA and product documentation for the actual analytical results. A general catalog statement should not be treated as a substitute for lot-specific documentation.

Researchers should assess, where applicable:

• Peptide identity
• Reported purity
• Molecular mass (useful for confirming No DAC vs. With DAC identity)
• Analytical testing method
• Lot or batch number
• Manufacturing documentation
• Storage requirements
• Product formulation
• Expiration or retest information, when provided

No certification, regulatory approval, or quality claim should be inferred unless it is explicitly documented by the manufacturer or relevant regulatory authority.

Storage and handling requirements should be determined from the current CJC-1295 No DAC Spray product documentation and lot-specific instructions.

General laboratory considerations include:

• Follow the storage conditions supplied with the product.
• Protect the material from inappropriate temperature, light, and environmental exposure.
• Keep the container properly closed when not being used in an approved research workflow.
• Avoid unnecessary temperature cycling.
• Maintain appropriate laboratory labeling and inventory records.
• Follow institutional procedures for handling research peptides.
• Do not use material beyond the stated storage period or applicable retest date without appropriate laboratory qualification.
• Consult the current COA and product documentation for product-specific requirements.

Storage guidance should not be inferred from research protocols for CJC-1295 With DAC, or from other CJC-1295 No DAC preparations, because formulation, conjugation chemistry, and packaging can affect stability.

Helix Bio's website describes research materials as being supplied to laboratories and institutions in the United States and describes tracked shipping and cold-chain handling within its fulfillment process.

Because shipping conditions, packaging specifications, availability, and delivery requirements may change, researchers should review the current Helix Bio shipping information and product listing before ordering.

Product packaging should remain appropriately labeled and handled as research material after delivery. Researchers are responsible for following applicable institutional, federal, state, and local requirements governing research materials.

CJC-1295 No DAC Spray is sold by Helix Bio for research and laboratory purposes only. It is not intended for human or veterinary consumption, self-administration, diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition.

"Spray" describes this product's physical format and does not by itself establish an administration route. Helix Bio does not represent this product as intended for nasal, intranasal, mucosal, oral, sublingual, or any other specific route of use.

CJC-1295 is not an FDA-approved drug in the United States. FDA approval status should not be inferred from published research, product availability, or laboratory use. FDA explains that unapproved drugs have not undergone the agency's standard review for safety, effectiveness, and quality.

This product is not a dietary supplement, consumer wellness product, or medical treatment. Researchers are responsible for determining whether a material is appropriate for their intended experimental application and for complying with applicable institutional and regulatory requirements.